The Prognostic Role of Circulating Tumor Cells (CTCs) in Lung Cancer

Joanna Kapeleris; Joanna Kapeleris; Arutha Kulasinghe; Arutha Kulasinghe; Majid E. Warkiani; Majid E. Warkiani; Ian Vela; Ian Vela; Liz Kenny; Kenneth O'Byrne; Kenneth O'Byrne; Kenneth O'Byrne; Chamindie Punyadeera; Chamindie Punyadeera

doi:10.3389/fonc.2018.00311

Frontiers in Oncology (Aug 2018)

The Prognostic Role of Circulating Tumor Cells (CTCs) in Lung Cancer

Joanna Kapeleris,
Joanna Kapeleris,
Arutha Kulasinghe,
Arutha Kulasinghe,
Majid E. Warkiani,
Majid E. Warkiani,
Ian Vela,
Ian Vela,
Liz Kenny,
Kenneth O'Byrne,
Kenneth O'Byrne,
Kenneth O'Byrne,
Chamindie Punyadeera,
Chamindie Punyadeera

Affiliations

Joanna Kapeleris: School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, QLD, Australia
Joanna Kapeleris: Translational Research Institute, Brisbane, QLD, Australia
Arutha Kulasinghe: School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, QLD, Australia
Arutha Kulasinghe: Translational Research Institute, Brisbane, QLD, Australia
Majid E. Warkiani: School of Biomedical Engineering, University of Technology Sydney, Sydney, NSW, Australia
Majid E. Warkiani: Institute of Molecular Medicine, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Ian Vela: Department of Urology, Princess Alexandra Hospital, Woolloongabba, QLD, Australia
Ian Vela: Australian Prostate Cancer Research Centre, Institute of Health and Biomedical Innovation, Translational Research Institute, Queensland University of Technology, Princess Alexandra Hospital, Brisbane, QLD, Australia
Liz Kenny: School of Medicine, University of Queensland, Royal Brisbane and Women's Hospital, Central Integrated Regional Cancer Service, Queensland Health, Brisbane, QLD, Australia
Kenneth O'Byrne: School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, QLD, Australia
Kenneth O'Byrne: Translational Research Institute, Brisbane, QLD, Australia
Kenneth O'Byrne: Princess Alexandra Hospital, Queensland Health, Brisbane, QLD, Australia
Chamindie Punyadeera: School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, QLD, Australia
Chamindie Punyadeera: Translational Research Institute, Brisbane, QLD, Australia

DOI: https://doi.org/10.3389/fonc.2018.00311
Journal volume & issue: Vol. 8

Abstract

Read online

Lung cancer affects over 1. 8 million people worldwide and is the leading cause of cancer related mortality globally. Currently, diagnosis of lung cancer involves a combination of imaging and invasive biopsies to confirm histopathology. Non-invasive diagnostic techniques under investigation include “liquid biopsies” through a simple blood draw to develop predictive and prognostic biomarkers. A better understanding of circulating tumor cell (CTC) dissemination mechanisms offers promising potential for the development of techniques to assist in the diagnosis of lung cancer. Enumeration and characterization of CTCs has the potential to act as a prognostic biomarker and to identify novel drug targets for a precision medicine approach to lung cancer care. This review will focus on the current status of CTCs and their potential diagnostic and prognostic utility in this setting.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords